{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T08:08:43Z","timestamp":1790842123354,"version":"4.1.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,12,24]],"date-time":"2019-12-24T00:00:00Z","timestamp":1577145600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,12,24]],"date-time":"2019-12-24T00:00:00Z","timestamp":1577145600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/http:\/\/dx.doi.org\/10.13039\/100013733","name":"Ipsen Biopharmaceuticals","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/http:\/\/dx.doi.org\/10.13039\/100013733","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"published-print":{"date-parts":[[2020,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Introduction<\/jats:title>\n                <jats:p>Somatotroph pituitary tumours are often resistant to first-generation somatostatin analogues and can invade the surrounding structures, limiting the chances of curative surgery. Recent studies suggested that the immune microenvironment and pro-angiogenic factors can influence neuroendocrine tumour prognosis. In this study, we aimed to investigate the prognostic role of immune cell-specific markers and endocan, a proteoglycan involved in neoangiogenesis and cell adhesion, in a cohort of acromegaly patients who underwent pituitary surgery as first-line treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Subjects and methods<\/jats:title>\n                <jats:p>Sixty four eligible subjects were identified. CD4+, CD8+ and CD68+ cells and endocan expression were evaluated by immunohistochemistry and results correlated with clinical and neuroradiological findings. Responsiveness to somatostatin analogues was assessed in patients with persistent disease following surgery.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The number of CD8+ lymphocytes was significantly lower in tumours with cavernous sinus invasion (median 0.2\/HPF, IQR: 2.2) compared with those without cavernous sinus invasion (median 2.4\/HPF, IQR: 2.3; <jats:italic>P<\/jats:italic>\u2009=\u20090.04). Tumours resistant to first-generation somatostatin analogues had lower CD8+ lymphocytes (median 1\/HPF, IQR: 2.4) compared with responders (median 2.4\/HPF, IQR: 2.9; <jats:italic>P<\/jats:italic>\u2009=\u20090.005). CD4+ lymphocytes were observed sporadically. The number of CD68+ macrophages and the endothelial or tumour cell endocan expression did not differ based on tumour size, cavernous sinus invasion or treatment responsiveness.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Our study suggests that a lower number of CD8+ lymphocytes is associated with cavernous sinus invasion and resistance to treatment with first-generation somatostatin analogues in acromegaly patients. These results highlight a potential role of the tumour immune microenvironment in determining the prognosis of somatotroph pituitary tumours.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s12020-019-02145-y","type":"journal-article","created":{"date-parts":[[2020,2,3]],"date-time":"2020-02-03T14:05:01Z","timestamp":1580738701000},"page":"651-658","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Tumour-infiltrating cytotoxic T lymphocytes in somatotroph pituitary neuroendocrine tumours"],"prefix":"10.1007","volume":"67","author":[{"given":"Donato","family":"Iacovazzo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9241-2392","authenticated-orcid":false,"given":"Sabrina","family":"Chiloiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eivind","family":"Carlsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Bianchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Giampietro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommaso","family":"Tartaglione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Bima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Elena","family":"Bracaccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Lugli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liverana","family":"Lauretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmelo","family":"Anile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Gessi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesare","family":"Colosimo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Rindi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Pontecorvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e1rta","family":"Korbonits","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"De Marinis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,12,24]]},"reference":[{"issue":"4","key":"2145_CR1","doi-asserted-by":"publisher","first-page":"C5","DOI":"10.1530\/ERC-17-0004","volume":"24","author":"SL Asa","year":"2017","unstructured":"S.L. Asa, O. Casar-Borota, P. Chanson et al. From pituitary adenoma to pituitary neuroendocrine tumor (PitNET): an International Pituitary Pathology Club proposal. Endocr. Relat. Cancer 24(4), C5\u2013C8 (2017). https:\/\/doi.org\/10.1530\/ERC-17-0004","journal-title":"Endocr. Relat. Cancer"},{"issue":"6","key":"2145_CR2","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1111\/j.1365-2265.2007.02825.x","volume":"66","author":"M Mercado","year":"2007","unstructured":"M. Mercado, F. Borges, H. Bouterfa et al. A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly. Clin. Endocrinol. 66(6), 859\u2013868 (2007). https:\/\/doi.org\/10.1111\/j.1365-2265.2007.02825.x","journal-title":"Clin. Endocrinol."},{"issue":"3","key":"2145_CR3","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1007\/s11102-014-0570-0","volume":"18","author":"AL Espinosa-de-los-Monteros","year":"2015","unstructured":"A.L. Espinosa-de-los-Monteros, B. Gonzalez, G. Vargas, E. Sosa, M. Mercado, Octreotide LAR treatment of acromegaly in \u201creal life\u201d: long-term outcome at a tertiary care center. Pituitary 18(3), 290\u2013296 (2015). https:\/\/doi.org\/10.1007\/s11102-014-0570-0","journal-title":"Pituitary"},{"issue":"3","key":"2145_CR4","doi-asserted-by":"publisher","first-page":"350","DOI":"10.4158\/EP15913.RA","volume":"22","author":"MH Shanik","year":"2016","unstructured":"M.H. Shanik, P.D. Cao, W.H. Ludlam, Historical response rates of somatostatin analogues in the treatment of acromegaly: a systematic review. Endocr. Pr. 22(3), 350\u2013356 (2016). https:\/\/doi.org\/10.4158\/EP15913.RA","journal-title":"Endocr. Pr."},{"issue":"7","key":"2145_CR5","doi-asserted-by":"publisher","first-page":"2746","DOI":"10.1210\/jc.2008-0126","volume":"93","author":"A Fusco","year":"2008","unstructured":"A. Fusco, M.C. Zatelli, A. Bianchi et al. Prognostic significance of the Ki-67 labeling index in growth hormone-secreting pituitary adenomas. J. Clin. Endocrinol. Metab. 93(7), 2746\u20132750 (2008). https:\/\/doi.org\/10.1210\/jc.2008-0126","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"2","key":"2145_CR6","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1530\/EJE-13-0349","volume":"169","author":"L Kasuki","year":"2013","unstructured":"L. Kasuki, L.E. Wildemberg, L.V. Neto, J. Marcondes, C.M. Takiya, M.R. Gadelha, Ki-67 is a predictor of acromegaly control with octreotide LAR independent of SSTR2 status and relates to cytokeratin pattern. Eur. J. Endocrinol. 169(2), 217\u2013223 (2013). https:\/\/doi.org\/10.1530\/EJE-13-0349","journal-title":"Eur. J. Endocrinol."},{"issue":"5","key":"2145_CR7","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.tem.2012.11.007","volume":"24","author":"MR Gadelha","year":"2013","unstructured":"M.R. Gadelha, L. Kasuki, M. Korbonits, Novel pathway for somatostatin analogs in patients with acromegaly. Trends Endocrinol. Metab. 24(5), 238\u2013246 (2013). https:\/\/doi.org\/10.1016\/j.tem.2012.11.007","journal-title":"Trends Endocrinol. Metab."},{"issue":"2","key":"2145_CR8","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1530\/EJE-15-0832","volume":"174","author":"D Iacovazzo","year":"2016","unstructured":"D. Iacovazzo, E. Carlsen, F. Lugli et al. Factors predicting pasireotide responsiveness in somatotroph pituitary adenomas resistant to first-generation somatostatin analogues: an immunohistochemical study. Eur. J. Endocrinol. 174(2), 241\u2013250 (2016). https:\/\/doi.org\/10.1530\/EJE-15-0832","journal-title":"Eur. J. Endocrinol."},{"issue":"6","key":"2145_CR9","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1111\/j.1750-3639.2012.00578.x","volume":"22","author":"A Cornelius","year":"2012","unstructured":"A. Cornelius, C. Cortet-Rudelli, R. Assaker et al. Endothelial expression of endocan is strongly associated with tumor progression in pituitary adenoma. Brain Pathol. 22(6), 757\u2013764 (2012). https:\/\/doi.org\/10.1111\/j.1750-3639.2012.00578.x","journal-title":"Brain Pathol."},{"issue":"3","key":"2145_CR10","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1007\/s11102-012-0434-4","volume":"16","author":"R Sanchez-Ortiga","year":"2013","unstructured":"R. Sanchez-Ortiga, L. Sanchez-Tejada, O. Moreno-Perez, P. Riesgo, M. Niveiro, A.M. Pico Alfonso, Over-expression of vascular endothelial growth factor in pituitary adenomas is associated with extrasellar growth and recurrence. Pituitary 16(3), 370\u2013377 (2013). https:\/\/doi.org\/10.1007\/s11102-012-0434-4","journal-title":"Pituitary"},{"issue":"3","key":"2145_CR11","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s11060-014-1377-6","volume":"117","author":"F Matano","year":"2014","unstructured":"F. Matano, D. Yoshida, Y. Ishii, S. Tahara, A. Teramoto, A. Morita, Endocan, a new invasion and angiogenesis marker of pituitary adenomas. J. Neurooncol. 117(3), 485\u2013491 (2014). https:\/\/doi.org\/10.1007\/s11060-014-1377-6","journal-title":"J. Neurooncol."},{"issue":"2","key":"2145_CR12","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1007\/s11102-015-0698-6","volume":"19","author":"Y Miao","year":"2016","unstructured":"Y. Miao, M. Zong, T. Jiang et al. A comparative analysis of ESM-1 and vascular endothelial cell marker (CD34\/CD105) expression on pituitary adenoma invasion. Pituitary 19(2), 194\u2013201 (2016). https:\/\/doi.org\/10.1007\/s11102-015-0698-6","journal-title":"Pituitary"},{"issue":"41","key":"2145_CR13","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000008262","volume":"96","author":"LY Lin","year":"2017","unstructured":"L.Y. Lin, Y.C. Yeh, C.H. Chu et al. Endocan expression is correlated with poor progression-free survival in patients with pancreatic neuroendocrine tumors. Medicine 96(41), e8262 (2017). https:\/\/doi.org\/10.1097\/MD.0000000000008262","journal-title":"Medicine"},{"key":"2145_CR14","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.gene.2016.12.012","volume":"603","author":"W He","year":"2017","unstructured":"W. He, L. Huang, X. Shen et al. Relationship between RSUME and HIF-1alpha\/VEGF-A with invasion of pituitary adenoma. Gene 603, 54\u201360 (2017). https:\/\/doi.org\/10.1016\/j.gene.2016.12.012","journal-title":"Gene"},{"issue":"9","key":"2145_CR15","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1097\/MPA.0000000000001150","volume":"47","author":"A da Silva","year":"2018","unstructured":"A. da Silva, M. Bowden, S. Zhang et al. Characterization of the neuroendocrine tumor immune microenvironment. Pancreas 47(9), 1123\u20131129 (2018). https:\/\/doi.org\/10.1097\/MPA.0000000000001150","journal-title":"Pancreas"},{"issue":"19\u201320","key":"2145_CR16","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1101\/gad.314617.118","volume":"32","author":"H Gonzalez","year":"2018","unstructured":"H. Gonzalez, C. Hagerling, Z. Werb, Roles of the immune system in cancer: from tumor initiation to metastatic progression. Genes Dev. 32(19\u201320), 1267\u20131284 (2018). https:\/\/doi.org\/10.1101\/gad.314617.118","journal-title":"Genes Dev."},{"issue":"2","key":"2145_CR17","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.it.2018.12.003","volume":"40","author":"F Souza-Fonseca-Guimaraes","year":"2019","unstructured":"F. Souza-Fonseca-Guimaraes, J. Cursons, N.D. Huntington, The emergence of natural killer cells as a major target in cancer immunotherapy. Trends Immunol. 40(2), 142\u2013158 (2019). https:\/\/doi.org\/10.1016\/j.it.2018.12.003","journal-title":"Trends Immunol."},{"key":"2145_CR18","doi-asserted-by":"publisher","unstructured":"Y. Togashi, K. Shitara, H. Nishikawa, Regulatory T cells in cancer immunosuppression - implications for anticancer therapy. Nat. Rev. Clin. Oncol., (2019). https:\/\/doi.org\/10.1038\/s41571-019-0175-7","DOI":"10.1038\/s41571-019-0175-7"},{"issue":"1","key":"2145_CR19","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.cell.2010.03.014","volume":"141","author":"BZ Qian","year":"2010","unstructured":"B.Z. Qian, J.W. Pollard, Macrophage diversity enhances tumor progression and metastasis. Cell 141(1), 39\u201351 (2010). https:\/\/doi.org\/10.1016\/j.cell.2010.03.014","journal-title":"Cell"},{"issue":"3","key":"2145_CR20","doi-asserted-by":"publisher","first-page":"172","DOI":"10.3109\/10520295.2011.577754","volume":"87","author":"SM Zhang","year":"2012","unstructured":"S.M. Zhang, L. Zuo, Q. Zhou et al. Expression and distribution of endocan in human tissues. Biotech. Histochem. 87(3), 172\u2013178 (2012). https:\/\/doi.org\/10.3109\/10520295.2011.577754","journal-title":"Biotech. Histochem."},{"issue":"15","key":"2145_CR21","doi-asserted-by":"publisher","first-page":"4575","DOI":"10.1158\/1078-0432.CCR-06-0185","volume":"12","author":"BD Grigoriu","year":"2006","unstructured":"B.D. Grigoriu, F. Depontieu, A. Scherpereel et al. Endocan expression and relationship with survival in human non-small cell lung cancer. Clin. Cancer Res. 12(15), 4575\u20134582 (2006). https:\/\/doi.org\/10.1158\/1078-0432.CCR-06-0185","journal-title":"Clin. Cancer Res."},{"issue":"23","key":"2145_CR22","doi-asserted-by":"publisher","first-page":"5422","DOI":"10.3748\/wjg.v22.i23.5422","volume":"22","author":"Y Chang","year":"2016","unstructured":"Y. Chang, W. Niu, P.L. Lian et al. Endocan-expressing microvessel density as a prognostic factor for survival in human gastric cancer. World J. Gastroenterol. 22(23), 5422\u20135429 (2016). https:\/\/doi.org\/10.3748\/wjg.v22.i23.5422","journal-title":"World J. Gastroenterol."},{"issue":"2","key":"2145_CR23","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s10549-016-4057-8","volume":"161","author":"A Sagara","year":"2017","unstructured":"A. Sagara, K. Igarashi, M. Otsuka et al. Endocan as a prognostic biomarker of triple-negative breast cancer. Breast Cancer Res. Treat. 161(2), 269\u2013278 (2017). https:\/\/doi.org\/10.1007\/s10549-016-4057-8","journal-title":"Breast Cancer Res. Treat."},{"issue":"2","key":"2145_CR24","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1002\/jcp.27016","volume":"234","author":"H Sun","year":"2019","unstructured":"H. Sun, H. Zhang, K. Li et al. ESM-1 promotes adhesion between monocytes and endothelial cells under intermittent hypoxia. J. Cell. Physiol. 234(2), 1512\u20131521 (2019). https:\/\/doi.org\/10.1002\/jcp.27016","journal-title":"J. Cell. Physiol."},{"issue":"6","key":"2145_CR25","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1161\/CIRCRESAHA.115.304718","volume":"115","author":"SF Rocha","year":"2014","unstructured":"S.F. Rocha, M. Schiller, D. Jing et al. Esm1 modulates endothelial tip cell behavior and vascular permeability by enhancing VEGF bioavailability. Circ. Res. 115(6), 581\u2013590 (2014). https:\/\/doi.org\/10.1161\/CIRCRESAHA.115.304718","journal-title":"Circ. Res."},{"issue":"7","key":"2145_CR26","doi-asserted-by":"publisher","first-page":"3141","DOI":"10.1210\/jc.2009-2670","volume":"95","author":"A Giustina","year":"2010","unstructured":"A. Giustina, P. Chanson, M.D. Bronstein et al. A consensus on criteria for cure of acromegaly. J. Clin. Endocrinol. Metab. 95(7), 3141\u20133148 (2010). https:\/\/doi.org\/10.1210\/jc.2009-2670","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"4","key":"2145_CR27","first-page":"610","volume":"33","author":"E Knosp","year":"1993","unstructured":"E. Knosp, E. Steiner, K. Kitz, C. Matula, Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings. Neurosurgery 33(4), 610\u2013617 (1993)","journal-title":"Neurosurgery"},{"issue":"10","key":"2145_CR28","doi-asserted-by":"publisher","first-page":"2705","DOI":"10.1038\/bjc.2013.634","volume":"109","author":"AN Seo","year":"2013","unstructured":"A.N. Seo, H.J. Lee, E.J. Kim et al. Tumour-infiltrating CD8+ lymphocytes as an independent predictive factor for pathological complete response to primary systemic therapy in breast cancer. Br. J. Cancer 109(10), 2705\u20132713 (2013). https:\/\/doi.org\/10.1038\/bjc.2013.634","journal-title":"Br. J. Cancer"},{"key":"2145_CR29","unstructured":"D.J. Dabbs, Diagnostic immunohistochemistry. (Elsevier, Philadelphia, PA, USA, 2013)"},{"issue":"2","key":"2145_CR30","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1007\/s12022-008-9029-z","volume":"19","author":"A Obari","year":"2008","unstructured":"A. Obari, T. Sano, K. Ohyama et al. Clinicopathological features of growth hormone-producing pituitary adenomas: difference among various types defined by cytokeratin distribution pattern including a transitional form. Endocr. Pathol. 19(2), 82\u201391 (2008). https:\/\/doi.org\/10.1007\/s12022-008-9029-z","journal-title":"Endocr. Pathol."},{"issue":"11","key":"2145_CR31","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1038\/modpathol.3800954","volume":"20","author":"M Volante","year":"2007","unstructured":"M. Volante, M.P. Brizzi, A. Faggiano et al. Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: a proposal of scoring system correlated with somatostatin receptor scintigraphy. Mod. Pathol. 20(11), 1172\u20131182 (2007). https:\/\/doi.org\/10.1038\/modpathol.3800954","journal-title":"Mod. Pathol."},{"issue":"3","key":"2145_CR32","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1111\/jcmm.13440","volume":"22","author":"E Venegas-Moreno","year":"2018","unstructured":"E. Venegas-Moreno, M.C. Vazquez-Borrego, E. Dios et al. Association between dopamine and somatostatin receptor expression and pharmacological response to somatostatin analogues in acromegaly. J. Cell. Mol. Med. 22(3), 1640\u20131649 (2018). https:\/\/doi.org\/10.1111\/jcmm.13440","journal-title":"J. Cell. Mol. Med."},{"issue":"1","key":"2145_CR33","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1210\/jc.2009-1583","volume":"95","author":"I Lupi","year":"2010","unstructured":"I. Lupi, L. Manetti, P. Caturegli et al. Tumor infiltrating lymphocytes but not serum pituitary antibodies are associated with poor clinical outcome after surgery in patients with pituitary adenoma. J. Clin. Endocrinol. Metab. 95(1), 289\u2013296 (2010). https:\/\/doi.org\/10.1210\/jc.2009-1583","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"3","key":"2145_CR34","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s12022-015-9383-6","volume":"26","author":"JQ Lu","year":"2015","unstructured":"J.Q. Lu, B. Adam, A.S. Jack, A. Lam, R.W. Broad, C.L. Chik, Immune cell infiltrates in pituitary adenomas: more macrophages in larger adenomas and more T cells in growth hormone adenomas. Endocr. Pathol. 26(3), 263\u2013272 (2015). https:\/\/doi.org\/10.1007\/s12022-015-9383-6","journal-title":"Endocr. Pathol."},{"issue":"1","key":"2145_CR35","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s11060-018-2844-2","volume":"139","author":"PF Wang","year":"2018","unstructured":"P.F. Wang, T.J. Wang, Y.K. Yang et al. The expression profile of PD-L1 and CD8(+) lymphocyte in pituitary adenomas indicating for immunotherapy. J. Neurooncol. 139(1), 89\u201395 (2018). https:\/\/doi.org\/10.1007\/s11060-018-2844-2","journal-title":"J. Neurooncol."},{"issue":"6","key":"2145_CR36","doi-asserted-by":"publisher","first-page":"8509","DOI":"10.1002\/jcp.27782","volume":"234","author":"B Farhood","year":"2019","unstructured":"B. Farhood, M. Najafi, K. Mortezaee, CD8(+) cytotoxic T lymphocytes in cancer immunotherapy: a review. J. Cell Physiol. 234(6), 8509\u20138521 (2019). https:\/\/doi.org\/10.1002\/jcp.27782","journal-title":"J. Cell Physiol."},{"issue":"10","key":"2145_CR37","doi-asserted-by":"publisher","first-page":"3925","DOI":"10.1210\/jc.2018-01347","volume":"103","author":"AL Lin","year":"2018","unstructured":"A.L. Lin, P. Jonsson, V. Tabar et al. Marked response of a hypermutated ACTH-secreting pituitary carcinoma to ipilimumab and nivolumab. J. Clin. Endocrinol. Metab. 103(10), 3925\u20133930 (2018). https:\/\/doi.org\/10.1210\/jc.2018-01347","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"20","key":"2145_CR38","first-page":"5857","volume":"60","author":"S Shimura","year":"2000","unstructured":"S. Shimura, G. Yang, S. Ebara, T.M. Wheeler, A. Frolov, T.C. Thompson, Reduced infiltration of tumor-associated macrophages in human prostate cancer: association with cancer progression. Cancer Res. 60(20), 5857\u20135861 (2000)","journal-title":"Cancer Res."},{"issue":"5","key":"2145_CR39","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1158\/1078-0432.CCR-06-2073","volume":"13","author":"J Forssell","year":"2007","unstructured":"J. Forssell, A. Oberg, M.L. Henriksson, R. Stenling, A. Jung, R. Palmqvist, High macrophage infiltration along the tumor front correlates with improved survival in colon cancer. Clin. Cancer Res. 13(5), 1472\u20131479 (2007). https:\/\/doi.org\/10.1158\/1078-0432.CCR-06-2073","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"2145_CR40","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1677\/ERC-08-0036","volume":"15","author":"M Ryder","year":"2008","unstructured":"M. Ryder, R.A. Ghossein, J.C. Ricarte-Filho, J.A. Knauf, J.A. Fagin, Increased density of tumor-associated macrophages is associated with decreased survival in advanced thyroid cancer. Endocr. Relat. Cancer 15(4), 1069\u20131074 (2008). https:\/\/doi.org\/10.1677\/ERC-08-0036","journal-title":"Endocr. Relat. Cancer"},{"issue":"9","key":"2145_CR41","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1245\/s10434-011-1609-3","volume":"18","author":"B Wang","year":"2011","unstructured":"B. Wang, D. Xu, X. Yu et al. Association of intra-tumoral infiltrating macrophages and regulatory T cells is an independent prognostic factor in gastric cancer after radical resection. Ann. Surg. Oncol. 18(9), 2585\u20132593 (2011). https:\/\/doi.org\/10.1245\/s10434-011-1609-3","journal-title":"Ann. Surg. Oncol."},{"issue":"28","key":"2145_CR42","doi-asserted-by":"publisher","first-page":"3525","DOI":"10.1200\/JCO.2011.40.9169","volume":"30","author":"S Asgharzadeh","year":"2012","unstructured":"S. Asgharzadeh, J.A. Salo, L. Ji et al. Clinical significance of tumor-associated inflammatory cells in metastatic neuroblastoma. J. Clin. Oncol. 30(28), 3525\u20133532 (2012). https:\/\/doi.org\/10.1200\/JCO.2011.40.9169","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"2145_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/cas.12314","volume":"105","author":"Y Komohara","year":"2014","unstructured":"Y. Komohara, M. Jinushi, M. Takeya, Clinical significance of macrophage heterogeneity in human malignant tumors. Cancer Sci. 105(1), 1\u20138 (2014). https:\/\/doi.org\/10.1111\/cas.12314","journal-title":"Cancer Sci."},{"issue":"6","key":"2145_CR44","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1097\/SLA.0000000000000262","volume":"260","author":"IH Wei","year":"2014","unstructured":"I.H. Wei, C.M. Harmon, M. Arcerito, D.F. Cheng, R.M. Minter, D.M. Simeone, Tumor-associated macrophages are a useful biomarker to predict recurrence after surgical resection of nonfunctional pancreatic neuroendocrine tumors. Ann. Surg. 260(6), 1088\u20131094 (2014). https:\/\/doi.org\/10.1097\/SLA.0000000000000262","journal-title":"Ann. Surg."},{"issue":"11","key":"2145_CR45","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/S1471-4906(02)02302-5","volume":"23","author":"A Mantovani","year":"2002","unstructured":"A. Mantovani, S. Sozzani, M. Locati, P. Allavena, A. Sica, Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 23(11), 549\u2013555 (2002)","journal-title":"Trends Immunol."},{"issue":"1","key":"2145_CR46","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.bbcan.2005.08.004","volume":"1765","author":"S Sarrazin","year":"2006","unstructured":"S. Sarrazin, E. Adam, M. Lyon et al. Endocan or endothelial cell specific molecule-1 (ESM-1): a potential novel endothelial cell marker and a new target for cancer therapy. Biochim. Biophys. Acta 1765(1), 25\u201337 (2006). https:\/\/doi.org\/10.1016\/j.bbcan.2005.08.004","journal-title":"Biochim. Biophys. Acta"},{"issue":"2","key":"2145_CR47","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1167\/iovs.09-4006","volume":"51","author":"FM Recchia","year":"2010","unstructured":"F.M. Recchia, L. Xu, J.S. Penn, B. Boone, P.J. Dexheimer, Identification of genes and pathways involved in retinal neovascularization by microarray analysis of two animal models of retinal angiogenesis. Investig. Ophthalmol. Vis. Sci. 51(2), 1098\u20131105 (2010). https:\/\/doi.org\/10.1167\/iovs.09-4006","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"issue":"3","key":"2145_CR48","doi-asserted-by":"publisher","first-page":"221","DOI":"10.7150\/jca.7691","volume":"5","author":"K Ozaki","year":"2014","unstructured":"K. Ozaki, N. Toshikuni, J. George et al. Serum endocan as a novel prognostic biomarker in patients with hepatocellular carcinoma. J. Cancer 5(3), 221\u2013230 (2014). https:\/\/doi.org\/10.7150\/jca.7691","journal-title":"J. Cancer"}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-019-02145-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12020-019-02145-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-019-02145-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,23]],"date-time":"2020-12-23T00:03:13Z","timestamp":1608681793000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12020-019-02145-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,24]]},"references-count":48,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["2145"],"URL":"https:\/\/doi.org\/10.1007\/s12020-019-02145-y","relation":{},"ISSN":["1355-008X","1559-0100"],"issn-type":[{"value":"1355-008X","type":"print"},{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,24]]},"assertion":[{"value":"16 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"M.K. and L.D.M. received research grants from Ipsen. The other authors have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments. Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}